



**Milestone**<sup>™</sup>  
PHARMACEUTICALS

## Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022

MONTREAL and CHARLOTTE, N.C., May 17, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.

The pre-recorded fireside chat will become available on Tuesday, May 24, 2022 at 7:00am ET and can be accessed in the News & Events section of Milestone's website at [www.milestonepharma.com](http://www.milestonepharma.com). An archived replay of the presentation will be available on the same website for approximately 90 days following the presentation.

### About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit [www.milestonepharma.com](http://www.milestonepharma.com) and follow Milestone on Twitter at @MilestonePharma.

### Contact

David Pitts  
Argot Partners  
212-600-1902  
[david@argotpartners.com](mailto:david@argotpartners.com)



**Milestone**<sup>™</sup>  
PHARMACEUTICALS

View original content to download multimedia: <https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-the-hc-wainwright-global-investment-conference-301548550.html>

SOURCE Milestone Pharmaceuticals, Inc.